The inflammatory response is essential for cardiac repair after myocardial infarction (MI) but also contributes to post-infarction remodeling and heart failure. In the infarcted myocardium, signals activate toll-like receptors, complement, and reactive oxygen species, leading to cytokine and chemokine upregulation. Leukocytes remove dead cells and debris, setting the stage for scar formation. Timely suppression of inflammation is critical for healing, followed by activation of myofibroblasts that secrete matrix proteins. Transforming growth factor-β (TGF-β) family members are crucial for suppressing inflammation and activating a pro-fibrotic program. Understanding the pathophysiology of post-infarction remodeling is key to developing targeted therapies. Patients with prolonged inflammation may benefit from anti-IL-1 or anti-chemokine therapies, while those with exaggerated fibrogenic responses may require inhibition of the Smad3 cascade. Biomarker-based approaches are needed to identify patients with distinct pathophysiological responses and to implement inflammation-modulating strategies. In the early stages of MI, innate immune pathways are activated, leading to an inflammatory response that clears dead cells and debris. The proliferative phase involves mononuclear cells and macrophages secreting growth factors that recruit and activate myofibroblasts. Apoptosis of reparative cells marks the end of the proliferative phase, leading to scar formation. Alarmins, such as HMGB1, promote inflammation by activating pattern recognition receptors. Other DAMPs, like heat shock proteins and ATP, also activate immune responses. TLRs and complement activation are involved in the inflammatory response, with TLR2 and TLR4 playing critical roles. ROS contribute to leukocyte infiltration and chemotactic gradients. Chemokines and cytokines, such as TNF, IL-1β, and IL-6, are upregulated in the infarcted myocardium and mediate inflammatory responses. C-X-C and C-C chemokines recruit inflammatory leukocytes, while TNF and IL-1β promote inflammation and delay myofibroblast activation. IL-6 is involved in inflammatory and reparative signaling, and its inhibition may be beneficial in certain contexts. The inflammatory response involves various cell types, including macrophages, neutrophils, and fibroblasts, which contribute to tissue repair and remodeling. Inflammation is critical for repair but can lead to adverse remodeling if not properly regulated. Overactive inflammation is associated with chamber dilation and systolic dysfunction, while excessive fibrogenic responses can lead to diastolic heart failure. The balance between matrix-degrading and matrix-preserving signals is crucial for proper remodeling. TGF-β signaling is key in fibrosis and remodeling, with Smad3 playing a critical role. Anti-inflammatory strategies have had limited success in clinical trials, highlighting the complexity of the pathophysiology. Future approaches to modulate inflammation inThe inflammatory response is essential for cardiac repair after myocardial infarction (MI) but also contributes to post-infarction remodeling and heart failure. In the infarcted myocardium, signals activate toll-like receptors, complement, and reactive oxygen species, leading to cytokine and chemokine upregulation. Leukocytes remove dead cells and debris, setting the stage for scar formation. Timely suppression of inflammation is critical for healing, followed by activation of myofibroblasts that secrete matrix proteins. Transforming growth factor-β (TGF-β) family members are crucial for suppressing inflammation and activating a pro-fibrotic program. Understanding the pathophysiology of post-infarction remodeling is key to developing targeted therapies. Patients with prolonged inflammation may benefit from anti-IL-1 or anti-chemokine therapies, while those with exaggerated fibrogenic responses may require inhibition of the Smad3 cascade. Biomarker-based approaches are needed to identify patients with distinct pathophysiological responses and to implement inflammation-modulating strategies. In the early stages of MI, innate immune pathways are activated, leading to an inflammatory response that clears dead cells and debris. The proliferative phase involves mononuclear cells and macrophages secreting growth factors that recruit and activate myofibroblasts. Apoptosis of reparative cells marks the end of the proliferative phase, leading to scar formation. Alarmins, such as HMGB1, promote inflammation by activating pattern recognition receptors. Other DAMPs, like heat shock proteins and ATP, also activate immune responses. TLRs and complement activation are involved in the inflammatory response, with TLR2 and TLR4 playing critical roles. ROS contribute to leukocyte infiltration and chemotactic gradients. Chemokines and cytokines, such as TNF, IL-1β, and IL-6, are upregulated in the infarcted myocardium and mediate inflammatory responses. C-X-C and C-C chemokines recruit inflammatory leukocytes, while TNF and IL-1β promote inflammation and delay myofibroblast activation. IL-6 is involved in inflammatory and reparative signaling, and its inhibition may be beneficial in certain contexts. The inflammatory response involves various cell types, including macrophages, neutrophils, and fibroblasts, which contribute to tissue repair and remodeling. Inflammation is critical for repair but can lead to adverse remodeling if not properly regulated. Overactive inflammation is associated with chamber dilation and systolic dysfunction, while excessive fibrogenic responses can lead to diastolic heart failure. The balance between matrix-degrading and matrix-preserving signals is crucial for proper remodeling. TGF-β signaling is key in fibrosis and remodeling, with Smad3 playing a critical role. Anti-inflammatory strategies have had limited success in clinical trials, highlighting the complexity of the pathophysiology. Future approaches to modulate inflammation in